Phase 3 Readout
AXSM: Phase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety
December 1, 2026 · shift. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2026
- Company
- Axsome Therapeutics, Inc. (AXSM)
- Drug
- shift
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety
- Drug
- shift
- Indication
- Excessive Sleepiness; Shift-work Disorder